That HR is strongly implicated in defining the response of GCTs to CDDP is well-documented by the fact that XRCC2, a protein promoting CDDP resistance via HR and FA pathways [38, 39, 40], has been found mutated in two GCT patients [22]. Here, XRCC2 is linked to granular cell tumor.